BSE filing, NSE: SJS. Summary written from the filing by ALFA Finder's alert engine.
SJS Enterprises Ltd: key numbers
- Share price
- ₹2,033.30
- Market cap
- ₹6,557 Cr
- Revenue (annual)
- ₹955.1 Cr
- Net profit (annual)
- ₹170.7 Cr
- P/E (TTM)
- 31.2×Sector 30.9×
- Promoter holding
- 19.99%-0.16% QoQ
- FII holding
- 16.12%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SJS Enterprises Ltd
All →SJS Enterprises Board Meeting Date
S.J.S. Enterprises schedules a 4 November 2026 board meeting to approve unaudited quarterly results for September 2026. An earnings call follows on 5 November.
SJS Enterprises Other Announcement
S.J.S. Enterprises Ltd has submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, as required under SEBI regulations.
SJS Enterprises Capacity Expansion: ₹81 Cr Investment
S.J.S. Enterprises' subsidiary, SDEPL, will invest ₹81 Crore to establish a new manufacturing facility in Pune. The project is expected to be completed by September 2027.
- Value
- ₹81.00 Cr
- Execution
- September 2027
- built-up manufacturing area
- 60000.0 sq. ft.
SJS Enterprises Capacity Expansion: ₹49 Cr Investment
S.J.S. Enterprises' subsidiary, Walter Pack, will invest ₹49 Crore to consolidate three manufacturing plants into a single, larger facility in Pune by May 2027.
- Value
- ₹49.00 Cr
- Execution
- May 2027
- net built-up area addition
- 63086.0 Sq Ft
SJS Enterprises Capacity Expansion: ₹45 Cr Investment
S.J.S. Enterprises is expanding its Bengaluru facility capacity by 20% to meet demand. The Rs. 45 crore investment will see production commence in Q3 FY27.
- Value
- ₹45.00 Cr
- capacity expansion
- 20.0 %
SJS Enterprises Merger & Restructuring Worth ₹5 Cr
S.J.S. Enterprises invested ₹5 Crore in its wholly owned subsidiary SDEPL via a rights issue, consistent with previously approved investment limits.
- Value
- ₹5.00 Cr
Other board meeting date announcements
All →Jenburkt Pharmaceuticals Board Meeting Date
Jenburkt Pharmaceuticals has intimated that its Board will meet on 3 Nov 2026 to consider Q2/H1-26 financial results. No decision has been taken yet.
Kingfa Science & Technology (India) Board Meeting Date
Kingfa informed exchanges its Board meeting is scheduled for November 5, 2026, to consider Q1/H1 FY27 unaudited results. Trading window stays closed until 48 hours post-announcement.
Orient Press Board Meeting Date
Orient Press Ltd intimated its Board meeting is scheduled for 05/11/2026, inter alia to approve unaudited Q3 FY27 results. The trading window stays closed till 48 hours after the intimation on 07/11/2026.
Surya Roshni Board Meeting Date
Surya Roshni's board will meet on November 7, 2026, to approve Q2 FY27 unaudited results. Trading window stays closed until November 9.
Prerna Infrabuild Board Meeting Date
Prerna Infrabuild will convene its board on 04/11/2026 to consider quarter results. The meeting is proposed under Regulation 33 of the LODR.
JSL Industries Board Meeting Date
JSL Industries intimates that its Board will meet on 5 Nov 2026 to consider unaudited Q1/H1 results. The trading window closes from 1 Oct 2026 until results are public.